The role of CD109 antigen in glioma

doi:10.16352/j.issn.1001-6325.2024.12.1731

Abstract

Abstract: Leukocyte differentiation antigen CD109 (CD109) is a glycosylphosphatidylinositol (GPI)-associated cell surface antigen, belonging to the α-2 macroglobulin/C3, C4 and C5 super family complex, and is a transforming growth factor (TGF)-β/Smads co-receptor. CD109 regulates the occurrence and development of glioma and is closely related to drug resistance and recurrence of glioma. As a cell membrane protein, CD109 can be directly labeled by specific antibodies or enzymes, and may also be recognized by targeted vectors for drug delivery, which is expected to become an effective diagnostic molecular marker and pharmacological therapeutic target.

Key words: CD109, glioma, drug resistance, recurrence

CLC Number:

R739.41

ZHOU Pinghui, CAO Sijie, YUE Dong, DONG Fengyun. The role of CD109 antigen in glioma[J]. Basic & Clinical Medicine, 2024, 44(12): 1731-1735.

References

[1]Filppu P, Tanjore Ramanathan J, Granberg KJ, et al. Cd109-gp130 interaction drives glioblastoma stem cell plasticity and chemoresistance through stat3 activity[J]. JCI Insight, 2021, 6:e141486. doi: 10.1172/jci.insight.141486.
[2]Turos-Cabal M, Sanchez-Sanchez AM, Puente-Moncada N, et al. Endoplasmic reticulum regulation of glucose metabolism in glioma stem cells[J]. Int J Oncol, 2024,64:1. doi: 10.3892/ijo.2023.5589.
[3]He X, Zhang K, Liu D, et al. Predictors of seizure outcomes in patients with diffuse low-grade glioma-related epilepsy after complete glioma removal[J]. CNS Neurosci Ther, 2023, 29: 736-743.
[4]Kim JS, Shin MJ, Lee SY, et al. Cd109 promotes drug resistance in a2780 ovarian cancer cells by regulating the stat3-notch1 signaling axis[J]. Int J Mol Sci, 2023,24:10306. doi: 10.3390/ijms241210306.
[5]Hagiwara S, Sasaki E, Hasegawa Y, et al. Serum Cd109 levels reflect the node metastasis status in head and neck squamous cell carcinoma[J]. Cancer Med, 2021, 10: 1335-1346.
[6]Lin M, Sutherland DR, Horsfall W, et al. Cell surface antigen cd109 is a novel member of the alpha(2) macroglobulin/c3, c4, c5 family of thioester-containing proteins[J]. Blood, 2002, 99: 1683-1691.
[7]Xu H, Yin Y, Li Y, et al. Flot2 promotes nasopharyngeal carcinoma progression through suppression of tgf-beta pathway via facilitating cd109 expression[J]. iScience, 2023, 27:108580. doi: 10.1016/j.isci.2023.108580.
[8]Zhou S, Hassan A, Kungyal T, et al. Cd109 is a critical determinant of egfr expression and signaling, and tumorigenicity in squamous cell carcinoma cells[J]. Cancers (Basel), 2022,14:3672. doi: 10.3390/cancers14153672.
[9]Luckstadt W, Rathod M, Mobus L, et al. Cd109 drives pro-tumorigenic cell properties in human non-small cell lung cancer through interaction with desmoglein-2[J]. Res Sq, 2024:rs.3.rs-4102385. doi: 10.21203/rs.3.rs-4102385/v1.
[10]Shen K, Zhu J, Zhou S, et al. Epithelial membrane protein-3 and chitinase-3-like protein-1 as new prognostic predictors of glioma, a two-gene study[J]. Curr Oncol, 2023, 30: 8686-8702.
[11]Zheng L, He JJ, Zhao KX, et al. Expression of overall survival-emt-immune cell infiltration genes predict the prognosis of glioma[J]. Noncoding RNA Res, 2024, 9: 407-420.
[12]Jensen KT, Nielsen NS, Viana Almeida A, et al. Proteolytic cleavage of the tgfbeta co-receptor cd109 changes its conformation, resulting in protease inhibition via activation of its thiol ester, and dissociation from the cell membrane[J]. FEBS J, 2024,291:3169-3190.
[13]Cuppini L, Calleri A, Bruzzone MG, et al. Prognostic value of Cd109⁺ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan[J]. PLoS One, 2013, 8: e74345.doi: 10.1371/journal.pone.0074345.
[14]Shiraki Y, Mii S, Enomoto A, et al. Significance of perivascular tumour cells defined by Cd109 expression in progression of glioma[J]. J Pathol, 2017, 243: 468-480.
[15]Zhang JM, Murakumo Y, Hagiwara S, et al. Cd109 attenuates tgf-beta1 signaling and enhances egf signaling in sk-mg-1 human glioblastoma cells[J]. Biochem Biophys Res Commun, 2015, 459: 252-258.
[16]Huang LH, Rau CS, Wu SC, et al. Identification and characterization of hadsc-derived exosome proteins from different isolation methods[J]. J Cell Mol Med, 2021, 25: 7436-7450.
[17]Bastola S, Pavlyukov MS, Yamashita D, et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy[J]. Nat Commun, 2020, 11: 4660.doi: 10.1038/s41467-020-18189-y.
[18]Yuan H, Jiang T, Zhang WD, et al. Multiomics and bioinformatics identify differentially expressed effectors in the brain of toxoplasma gondii infected masked palm civet[J]. Front Cell Infect Microbiol, 2023, 13: 1267629.doi: 10.3389/fcimb.2023.1267629.
[19]Huang H, Shah H, Hao J, et al. Lncrna lucat1 promotes glioblastoma progression by enhancing hif1alpha activity[J]. Neuro Oncol, 2024,26:1388-1401.
[20]Minata M, Audia A, Shi J, et al. Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation[J]. Cell Rep, 2019, 26: 1893-1905 e7.
[21]Xu D, Cao M, Wang B, et al. Epigenetically regulated lncrnas dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas[J]. Theranostics, 2023, 13: 1490-1505.
[22]Wang L, Zhou X, Chen X, et al. Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-pd-1 antibody and il-12[J]. Mol Ther Oncol, 2024, 32: 200799.doi:10.1016/j.omton.2024.200799.
[23]Lohmeier J, Radbruch H, Brenner W, et al. Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multi-modal and integrative 18f-fet pet/fast-dki approach[J]. Eur Radiol, 2024, 34: 2487-2499.
[24]Li H, Zhu J, Liu X, et al. Glioma stem cell-derived exosomes induce the transformation of astrocytes via the mir-3065-5p/dlg2 signaling axis[J]. Glia, 2024, 72: 857-871.